Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

7.710 +0.210 (+2.80%)
Streaming Delayed Price Updated: 10:37 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vir Biotechnology, Inc. - Common Stock

News headline image
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
From Vir Biotechnology, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.